|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The atopic dermatitis market is anticipated to grow at a CAGR of 7.8% during the forecast period, 2022-2027.
The COVID-19 pandemic has significantly impacted the atopic dermatitis market. As per a March 2022 published article titled "Association between atopic dermatitis and COVID-19 infection: A case-control study in the All of Us research program", atopic dermatitis is associated with increased odds of COVID-19 infection even after controlling common comorbidities. Additionally, as per a February 2022 published study titled "Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients", the results revealed that atopic dermatitis during the COVID-19 pandemic was associated with a lower overall health rating, life satisfaction, and impaired quality of life (QoL) related to mental health in a Polish population. Thus, several initiatives are being introduced to manage COVID-19 patients suffering from atopic dermatitis. For instance, as per a June 2020 update, the SECURE-AD Patient survey is designed to help understand how the coronavirus pandemic (COVID-19) affects people with atopic dermatitis (also called atopic eczema). It is encouraging the patient population with atopic dermatitis around the world to participate and report their experience with COVID-19 infection using this survey. Thus, the ongoing pandemic is expected to drive the demand for the treatment of atopic dermatitis, thereby increasing the market's growth.
Further, the significant factors fueling the market's growth are the increasing burden of allergic reactions; an important role played by food allergy; and increasing environmental pollution.
The increasing burden of allergic reactions, with a significant role in food allergies, is driving the market's growth. For instance, a 2020 Food Allergy Research & Education report estimates that 32 million United States residents have food allergies, including 5.6 million children under age 18. About 40% of children with food allergies are allergic to more than one food. Additionally, as per a May 2021 update by the Australian Society of Clinical Immunology and Allergy (ASCIA), food allergy occurs in around 10% of infants, 4–8% of children, and about 2% of adults in Australia and New Zealand. Moreover, according to a February 2020 published article titled "Recent Survey on Food Allergy Prevalence," food allergy is a significant public health issue. It affects an estimated 3% to 10% of adults and 8% of children worldwide. Likewise, as per a June 2020 published article titled "Atopic dermatitis and its relation to food allergy," infants with temporary skin barrier disruption and persistent atopic dermatitis are particularly at risk of developing food allergy, with up to half of the patients demonstrating positive food-specific IgE and one-third of severe cases of atopic dermatitis having positive symptoms on an oral food challenge. As per the same study, many children with atopic dermatitis exhibit asymptomatic sensitization to foods. As food allergies result in atopic dermatitis, the increasing burden of allergic reactions across the globe is anticipated to increase the demand for treating atopic dermatitis worldwide, propelling the market growth.
Additionally, the approvals from the regulatory authorities are propelling the growth of the market. For instance, in December 2021, LEO Pharma Inc. reported that the United States Food and Drug Administration (USFDA) has approved Adbry (tralokinumab-Adam) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, severe adverse effects of certain therapeutic drugs significantly hinder the market's growth.
Scope of the Report
As per the scope of this report, atopic dermatitis, also known as atopic eczema, is often related as just a ‘skin condition,’ a misconception people think can be dealt with on their own. However, it impacts the patient’s life physically and emotionally. The market is segmented by Drug Class (Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, and Other Drug Classes), Route of Administration (Topical, Oral, and Injectable), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
|By Drug Class|
|IL-4 and PDE4 Inhibitors|
|Other Drug Classes|
|By Route of Administration|
Key Market Trends
Corticosteroids Segment Dominated the Atopic Dermatitis Market Over the Analysis Period
By drug class, the corticosteroid segment is anticipated to witness significant growth. Corticosteroids are referred to as cortisone-like medicines that are used as pain relief medications for inflammation in the body. These drugs are known to reduce itching, swelling, allergic reactions, and redness. The major factors fueling the segment's growth are the rising innovations leading to the advent of counterfeit medicines and alternative drugs, and strategic initiatives undertaken by the market players.
As per the 2022 National Eczema Association, corticosteroids are the most commonly prescribed medications for all types of eczema, reducing inflammation and itching so that the skin can begin to heal. Corticosteroids have been used for over 60 years as topical medications to treat many inflammatory skin conditions, including eczema.
Moreover, in December 2021, Eli Lilly reported that lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in the third Phase 3 study. Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
To understand key trends, Download Sample Report
North America is Expected to Witness a Significant Growth over the Forecast Period
Within North America, the United States is expected to hold a significant share of the market. The major factors fueling the market's growth are the increasing prevalence of atopic dermatitis, high treatment awareness among the patient population across the United States, well-established healthcare infrastructure, and early adoption of novel medications. For instance, as per the 2022 National Eczema Association, an estimated 16.5 million United States adults (7.3%) have atopic dermatitis that initially began at more than two years of age, with nearly 40% affected by moderate or severe disease.
In addition, better reimbursement policies and increasing business partnerships of pharmaceutical companies with contract research organizations in the emerging markets, along with product developments, are boosting the market's growth. For instance, in February 2022, Evelo Biosciences, Inc., a clinical-stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory diseases, reported that the first patient had been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.
Also, in February 2021, the United States Food and Drug Administration accepted the Priority Review of New Drug Application (NDA) for Ruxolitinib Cream by Incyte Corporation, which is a selective JAK1/JAK2 inhibitor designed for topical application as a treatment for atopic dermatitis (AD), a type of eczema.
Moreover, the growing number of investments in atopic dermatitis contributes to the market's growth. For instance, as per a June 2021 published article titled "Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)" by the National Health Institutes (NIH), the estimated funding for atopic dermatitis research was USD 46 million in 2021 and USD 44 million in 2022.
Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.
To understand geography trends, Download Sample Report
The atopic dermatitis market is a moderately competitive market with major players dominating the market. The presence of major market players, such as Pfizer Inc., Novartis International AG, Allergan PLC, and Abbvie Inc., is increasing the overall competitive rivalry of the market studied. Large organizations rely heavily on advertising expenses and branding strategies. They are also collaborating with successful personalities, initiatives, or programs at the national level, which promote their product, thereby allowing them to be recognized earlier than other brands in the market studied.
Bristol Myers Squibb
Regeneron Pharmaceuticals, Inc.
Evelo Biosciences, Inc.
- In June 2022, Sanofi received United States Food and Drug Administration (FDA) approval for Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- In February 2022, Evelo Biosciences, Inc., a clinical-stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, reported that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Allergic Reactions with Major Role of Food Allergy
4.2.2 Increasing Environmental Pollution
4.3 Market Restraints
4.3.1 Serious Adverse Effects Related to Certain Therapeutic Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug Class
5.1.3 IL-4 and PDE4 Inhibitors
5.1.4 Calcineurin Inhibitors
5.1.6 Other Drug Classes
5.2 By Route of Administration
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.3.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Allergan PLC
6.1.3 Bausch Health Companies Inc.
6.1.4 GlaxoSmithKline PLC
6.1.5 Nestle SA
6.1.6 Pfizer Inc.
6.1.7 Regenron Pharmaceutical Inc.
6.1.8 Evelo Biosciences
6.1.9 Cara Therapeutics
6.1.10 Bristol-Myers Squibb Company
6.1.11 Sanofi S.A.
6.1.12 LEO Pharma
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Atopic Dermatitis Market market is studied from 2019 - 2027.
What is the growth rate of Global Atopic Dermatitis Market?
The Global Atopic Dermatitis Market is growing at a CAGR of 7.8% over the next 5 years.
Which region has highest growth rate in Global Atopic Dermatitis Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Atopic Dermatitis Market?
North America holds highest share in 2021.
Who are the key players in Global Atopic Dermatitis Market?
Pfizer Inc., Abbvie Inc., Bristol Myers Squibb, Regeneron Pharmaceuticals, Inc., Evelo Biosciences, Inc. are the major companies operating in Global Atopic Dermatitis Market.